BMS – media

Bristol-Myers Squibb’s Opdivo Ensures a Lung Cancer Position

Bristol-Myers Squibb secured a standing in the small cell lung cancer domain making up for its slower growth in the non-small cell lung cancer market compared to its counterpart, Merck.
- Source: FiercePharma
- 1,285
- August 22, 2018
BMS cancer FDA New Approvals
Flatiron Health, acquired By Roche, Signs Three-Year Deal with Bristol-Myers

Flatiron announced a three-year agreement with Bristol-Myers Squibb (BMS) a leading pharma company from the US. BMS is planning to use Flatiron’s expertise to expand real-world evidence to develop Bristol’s experimental cancer drugs.
- Source: drugdu
- 683
- May 4, 2018
BMS Company Insights Roche
BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in patients whose cancers have a high tumour mutation burden (TMB), regardless of PD-L1 expression.
- Source: pharmafile
- 568
- February 7, 2018
BMS Chemotherapy NSCLC Opdivo TMB Yervoy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.